- Home
- CURR vs ENTX Comparison
CURR vs ENTX Comparison
Compare CURR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- ENTX
- Stock Information
- Founded
- CURR 2013
- ENTX 2010
- Country
- CURR Singapore
- ENTX Israel
- Employees
- CURR 244
- ENTX N/A
- Industry
- CURR Business Services
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURR Consumer Discretionary
- ENTX Health Care
- Exchange
- CURR Nasdaq
- ENTX Nasdaq
- Market Cap
- CURR 74.0M
- ENTX 69.6M
- IPO Year
- CURR N/A
- ENTX 2018
- Fundamental
- Price
- CURR $1.54
- ENTX $1.79
- Analyst Decision
- CURR Strong Buy
- ENTX Strong Buy
- Analyst Count
- CURR 1
- ENTX 1
- Target Price
- CURR $3.50
- ENTX $10.00
- AVG Volume (30 Days)
- CURR 101.0K
- ENTX 30.9K
- Earning Date
- CURR 04-16-2025
- ENTX 05-09-2025
- Dividend Yield
- CURR N/A
- ENTX N/A
- EPS Growth
- CURR N/A
- ENTX N/A
- EPS
- CURR N/A
- ENTX N/A
- Revenue
- CURR $46,435,412.00
- ENTX $181,000.00
- Revenue This Year
- CURR N/A
- ENTX N/A
- Revenue Next Year
- CURR N/A
- ENTX N/A
- P/E Ratio
- CURR N/A
- ENTX N/A
- Revenue Growth
- CURR N/A
- ENTX N/A
- 52 Week Low
- CURR $1.19
- ENTX $1.41
- 52 Week High
- CURR $7.08
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- ENTX 49.59
- Support Level
- CURR N/A
- ENTX $1.50
- Resistance Level
- CURR N/A
- ENTX $1.84
- Average True Range (ATR)
- CURR 0.00
- ENTX 0.11
- MACD
- CURR 0.00
- ENTX 0.03
- Stochastic Oscillator
- CURR 0.00
- ENTX 85.50
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.